A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19
Completed
Ridgeback Biotherapeutics, LP
Phase 2
This is a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare
the safety, tolerability, and antiviral activity of EIDD-2801 versus placebo as measured by
infectious virus detection in symptomatic adult outpatients with COVID-19
The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
Recruiting
Ridgeback Biotherapeutics, LP
Phase 2
Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the
efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults
with polymerase chain reaction (PCR)-Confirmed COVID-19.
The AGILE platform master protocol allows incorporation of a range of identified and
yet-to-be-identified candidates as potential treatments for adults with COVID-19 into the
trial. Candidates will be added into the trial via candidate-specific trial (CST) protocols
of this master protocol as appendices. Having one master protocol ensures different
candidates are evaluated in the same consistent manor and opening up new trials for new
candidates is more efficient. Inclusion of new candidates will be determined by the AGILE
Scientific Advisory Board based on pre-clinical data, evidence in the clinical setting and
GMP capabilities.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
